Atlas Trials

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1

Clinical trial NCT06777264 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06777264
Sponsor
First Affiliated Hospital of Zhejiang University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Lymphoblastic LeukemiaB Cell ALL
Start date
2025-01-15
Primary completion
2026-12-15
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.